Seeking to defend its growing proteomics patent portfolio, Invitrogen sued Bio-Rad Laboratories earlier this month claiming that some of its electrophoresis gels infringe upon certain Invitrogen patents, BioCommerce Week has learned.
The suit, filed on April 8 with the United States District Court of the Southern District of California, alleges that a number of Bio-Rad's Criterion XT gels infringe three patents owned by Invitrogen: U.S. Patent No. 5,922,185, No. 6,162,338, and No. 6,783,651.